文献速递基础与转化研究新药、器械与细胞基因治疗研发

人自体移植后基因工程造血干祖细胞的动态研究

Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans.
PubMed 文献 · Nat Med · 2018-10-01

本研究通过追踪6例接受慢病毒基因治疗联合自体造血干祖细胞(HSPC)移植患者长达5年的148,093个独立克隆,系统分析了7种HSPC亚型的频率、动态与输出。研究发现原始多能祖细胞与造血干细胞在移植后初始重建期与后续稳态期角色不同,部分体外激活的HSC具有延迟激活特性,且早期淋系偏向祖细胞可能长期存活而不依赖HSC持续产生。

要点

  • 追踪6例患者148,093个克隆揭示7种HSPC亚型移植后动态差异
  • 原始多能祖细胞与HSC在初始重建与稳态期角色不同
  • 部分体外激活HSC移植后经历延迟激活期且具有韧性

核心结论

  • 人自体移植后HSPC各亚型在初始重建与稳态期具有不同动态角色,部分HSC延迟激活,早期淋系偏向祖细胞可能长期存活。

研究设计与样本

  • 追踪6例接受慢病毒基因治疗联合自体HSPC移植患者长达5年的148,093个独立克隆,分析7种HSPC亚型。

主要发现

  • 原始多能祖细胞与HSC在移植后初始重建期与后续稳态期角色不同。
  • 部分体外激活的HSC具有韧性并在移植后经历明确的延迟激活期。
  • 早期淋系偏向祖细胞可能具备长期存活能力,可独立于HSC的持续产生而维持。

临床怎么用

  • 为理解基因治疗联合自体HSPC移植后各亚型重建动力学提供人体数据参考。

局限性

  • 研究仅纳入6例患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic stem and progenitor cells (HSPC) are endowed with the role of generating and maintaining lifelong the extremely diverse pool of blood cells1. Clinically, transplantation of human HSPC from an allogeneic healthy donor or infusion of autologous gene-corrected HSPC can effectively replenish defective blood cell production caused by congenital or acquired disorders2-9. However, due to methodological and ethical constraints that have limited the study of human HSPC primarily to in vitro assays10 or xenotransplantation models11,12, the in vivo activity of HSPC has to date remained relatively unexplored in humans13-16. Here we report a comprehensive study of the frequencies, dynamics and output of seven HSPC subtypes in humans that was performed by tracking 148,093 individual clones in six patients treated with lentiviral gene therapy using autologous HSPC transplantation and followed for up to 5 years. We discovered that primitive multipotent progenitor and hematopoietic stem cell (HSC) populations have distinct roles during the initial reconstitution after transplant, compared with subsequent steady-state phases. Furthermore, we showed that a fraction of in vitro-activated HSC are resilient and undergo a defined delayed activation period upon transplant. Finally, our data support the concept that early lymphoid-biased progenitors might be capable of long-term survival, such that they can be maintained independently of their continuous production from HSC. Overall, this study provides comprehensive data on HSPC dynamics after autologous transplantation and gene therapy in humans.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Scala S, Basso-Ricci L, Dionisio F, et al. Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans. Nat Med. 2018. PMID: 30275570. doi:10.1038/s41591-018-0195-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。